12:00 AM
 | 
Dec 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PSI-7977: Phase II started

Pharmasset began an open-label, New Zealand Phase II trial in about 40 treatment-naive patients with HCV genotype 2 or 3 infection to evaluate 400 mg/day oral PSI-7977 plus ...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >